Revenue GrowthNGL Fine-Chem’s history of robust multi-year revenue growth reflects expanding product demand and market penetration in fine and specialty chemicals. Durable top-line expansion supports scale advantages, incremental margin recovery potential, and the ability to fund strategic investments over the next several quarters.

Equity BaseA steadily rising equity base and healthy equity ratio provide a durable capital cushion, improving solvency and enabling the company to absorb shocks or pursue growth without immediate reliance on external financing. This strengthens long-term funding flexibility and strategic optionality.

Operational Margin StabilityRelatively stable EBIT and EBITDA margins suggest the core chemical manufacturing operations possess cost controls and pricing ability. Sustained operational profitability underpins long-term cash generation potential and makes the business more resilient to cyclical demand swings over the medium term.

Bears Say

Free Cash Flow WeaknessPersistent negative free cash flow and low free-cash-flow-to-net-income indicate inefficiencies converting earnings into usable cash. Over several quarters this raises financing risk, constrains organic investment capacity, and may force reliance on debt or equity to fund capex or working capital.

Rising LeverageAn increasing debt-to-equity ratio signals rising financial leverage, which reduces balance-sheet flexibility and raises interest expense sensitivity. If margins or cash conversion remain uneven, higher leverage elevates refinancing and solvency risk over the medium term.

Profitability VariabilityA recent drop in net income and volatile margins point to inconsistent profitability driven by cost pressures or pricing dynamics. Variable returns weaken long-term reinvestment ability and make forecasting cash flows and returns on equity less reliable for strategic planning.

NGL Fine-Chem Ltd. News

NGL Fine-Chem Board Clears Q3 FY26 Results, Appoints New Company Secretary

NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) just unveiled an announcement. NGL Fine-Chem Ltd.’s board has approved the unaudited...

26d ago

NGL Fine-Chem Clears Q3 FY26 Results, Appoints New Compliance Head

An announcement from NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) is now available. NGL Fine-Chem Ltd. announced that its...

26d ago

NGL Fine-Chem Confirms SEBI-Compliant Dematerialisation of Securities for December Quarter

NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) has provided an update. NGL Fine-Chem Ltd. has informed the stock exchanges...

2M ago

NGL Fine-Chem Ltd. Announces Virtual AGM and E-Voting Details

An update from NGL Fine-Chem Ltd. ( ($IN:NGLFINE) ) is now available. NGL Fine-Chem Ltd. announced the details...

7M ago

NGLFINE FAQ

What was NGL Fine-Chem Ltd.’s price range in the past 12 months?

NGL Fine-Chem Ltd. lowest stock price was ₹985.05 and its highest was ₹2596.00 in the past 12 months.

What is NGL Fine-Chem Ltd.’s market cap?

NGL Fine-Chem Ltd.’s market cap is ₹14.17B.

When is NGL Fine-Chem Ltd.’s upcoming earnings report date?

NGL Fine-Chem Ltd.’s upcoming earnings report date is May 27, 2026 which is in 87 days.

How were NGL Fine-Chem Ltd.’s earnings last quarter?

NGL Fine-Chem Ltd. released its earnings results on Feb 03, 2026. The company reported ₹25.398 earnings per share for the quarter, beating the consensus estimate of N/A by ₹25.398.

Is NGL Fine-Chem Ltd. overvalued?

According to Wall Street analysts NGL Fine-Chem Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NGL Fine-Chem Ltd. pay dividends?

NGL Fine-Chem Ltd. pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.13%. See more information on NGL Fine-Chem Ltd. dividends here

What is NGL Fine-Chem Ltd.’s EPS estimate?

NGL Fine-Chem Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NGL Fine-Chem Ltd. have?

NGL Fine-Chem Ltd. has 6,178,024 shares outstanding.

What happened to NGL Fine-Chem Ltd.’s price movement after its last earnings report?

NGL Fine-Chem Ltd. reported an EPS of ₹25.398 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.203%.

Which hedge fund is a major shareholder of NGL Fine-Chem Ltd.?

Currently, no hedge funds are holding shares in IN:NGLFINE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NGL Fine-Chem Ltd.

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.